Get the Stockscreener App
1.31
9.66%
-0.14
Proqr Therapeutics N V stock is traded at $1.31, with a volume of 1.06M.
It is down -9.66% in the last 24 hours and down -29.57% over the past month.
ProQR Therapeutics NV is a biopharmaceutical company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber congenital amaurosis type 10, and dystrophic epidermolysis bullosa. The only reportable segment of the company is the discovery and development of different, RNA-based therapeutics. Geographically, the company operates in United States.
See More
Previous Close:
$1.45
Open:
$1.45
24h Volume:
1.06M
Relative Volume:
1.15
Market Cap:
$184.87M
Revenue:
$15.53M
Net Income/Loss:
$-52.71M
P/E Ratio:
-2.607
EPS:
-0.5025
Net Cash Flow:
$-59.00M
1W Performance:
-19.63%
1M Performance:
-29.57%
6M Performance:
-32.82%
1Y Performance:
-53.21%
1-Day Range:
$1.30
$1.49
1-Week Range:
$1.30
$1.70
52-Week Range:
$1.30
$3.10
Proqr Therapeutics N V Stock (PRQR) Company Profile
Compare PRQR vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PRQR
Proqr Therapeutics N V
|
1.31 | 184.87M | 15.53M | -52.71M | -59.00M | -0.5025 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Proqr Therapeutics N V Stock (PRQR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-26 | Initiated | BofA Securities | Buy |
| Mar-12-26 | Resumed | Oppenheimer | Outperform |
| Apr-29-25 | Resumed | Cantor Fitzgerald | Overweight |
| Apr-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-10-25 | Upgrade | Citigroup | Neutral → Buy |
| Jan-10-25 | Initiated | Oppenheimer | Outperform |
| Oct-29-24 | Upgrade | Raymond James | Outperform → Strong Buy |
| Nov-08-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Mar-30-23 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Dec-22-22 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Feb-14-22 | Downgrade | Citigroup | Buy → Neutral |
| Feb-11-22 | Downgrade | Raymond James | Strong Buy → Mkt Perform |
| Feb-11-22 | Downgrade | Stifel | Buy → Hold |
| Feb-01-22 | Initiated | Raymond James | Strong Buy |
| May-03-21 | Initiated | Stifel | Buy |
| Mar-25-21 | Reiterated | Citigroup | Buy |
| Nov-03-20 | Resumed | Cantor Fitzgerald | Overweight |
| Mar-12-19 | Reiterated | Chardan Capital Markets | Buy |
| Dec-19-18 | Initiated | RBC Capital Mkts | Outperform |
| Nov-15-18 | Initiated | Citigroup | Buy |
| Sep-19-18 | Initiated | Evercore ISI | Outperform |
| Sep-26-17 | Reiterated | JMP Securities | Mkt Outperform |
| Jun-20-16 | Initiated | Chardan Capital Markets | Neutral |
| Oct-15-14 | Initiated | Deutsche Bank | Buy |
| Oct-13-14 | Initiated | H.C. Wainwright | Buy |
View All
Proqr Therapeutics N V Stock (PRQR) Latest News
ProQR Therapeutics' (PRQR) Buy Rating Reaffirmed at Chardan Capital - MarketBeat
FY2028 Earnings Estimate for PRQR Issued By HC Wainwright - MarketBeat
Press Releases about ProQR Therapeutics N.V.Ordinary Shares (Nasdaq:PRQR) - FinancialContent
ProQR Therapeutics N.V.Ordinary Shares (PRQR) Stock Price, News, Quote & History - financialcontent.com
HC Wainwright Has Lowered Expectations for ProQR Therapeutics (NASDAQ:PRQR) Stock Price - MarketBeat
Price to sales forward of ProQR Therapeutics N.V. – SWB:0PQ - TradingView
Obesity Market to Witness Strong Growth and Significant Market Expansion by 2036 – DelveInsight | Rhythm Pharma, Boehringer Ingelheim, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical - Barchart.com
ProQR Therapeutics Initiates AX-0811 Clinical Trial Following First Participant Dosing - Kalkine Media
ProQR Therapeutics N.V.ADR Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Australia
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com Nigeria
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com South Africa
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com India
ProQR at Cantor conference: RNA editing pipeline gains speed By Investing.com - Investing.com UK
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com South Africa
ProQR Therapeutics Doses First Participant in Phase 1 Trial of Liver Disease Treatment - marketscreener.com
ProQR doses first participant in AX-0811 phase 1 trial - investing.com
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com Canada
ProQR Doses First Participant in Phase 1 Trial of AX-0811 for Cholestatic Liver Diseases - TipRanks
ProQR doses first participant in AX-0811 phase 1 trial By Investing.com - Investing.com India
A liver disease trial has dosed its first volunteer. ProQR expects early study data in January 2027. - Stock Titan
ProQR Therapeutics (NASDAQ:PRQR) Shares Cross Above 50 Day Moving AverageShould You Sell? - marketbeat.com
Enterprise value to EBIT forward of ProQR Therapeutics N.V. – NASDAQ:PRQR - TradingView
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
ProQR to Participate in Upcoming Investor Conferences in September 2026 - markets.businessinsider.com
ProQR to Participate in Upcoming Investor Conferences in September 2026 - The Manila Times
ProQR Therapeutics N.V. (NASDAQ:PRQR) Given Consensus Rating of "Moderate Buy" by Brokerages - marketbeat.com
ProQR Therapeutics N.V.ADR Financials – Balance Sheet, Profit & Loss, Cash Flow - Value Research
ProQR Therapeutics (NASDAQ:PRQR) Share Price Crosses Above 50-Day Moving AverageWhat's Next? - marketbeat.com
ProQR Therapeutics NV (PRQR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Certain Warrants of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
Certain Common Stock of ProQR Therapeutics N.V. are subject to a Lock-Up Agreement Ending on 24-AUG-2026. - marketscreener.com
ProQR Therapeutics: Buy For Axiomer RNA Tech Validation And Other Catalysts (NASDAQ:PRQR) - Seeking Alpha
ProQR Therapeutics starts with Buy rating on st... - Pluang
Price to sales forward of ProQR Therapeutics N.V. – FWB:0PQ - TradingView
PRQR Looks 1.8% Undervalued on GF Value™ at $2.45 - GuruFocus
PRQR Initiates Coverage by B of A Securities -- Price Target Ann - GuruFocus
ProQR a new buy at BoA on RNA-editing platform - Seeking Alpha
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com Canada
ProQR Therapeutics (NASDAQ:PRQR) Earns Buy Rating from Analysts at Bank of America - MarketBeat
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com India
BofA Securities initiates ProQR stock with buy on liver therapy By Investing.com - Investing.com UK
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
BofA Securities initiates ProQR stock with buy on liver therapy - Investing.com
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - vinanet.vn
ProQR (PRQR) Levels: Climbs 3.26% to $2.22 in the Latest Session; Key Range - siam.in
HC Wainwright Expects Lower Earnings for ProQR Therapeutics - MarketBeat
ProQR Therapeutics Virtual Investor Event Transcript - GuruFocus
Equities Analysts Set Expectations for PRQR FY2030 Earnings - MarketBeat
Proqr Therapeutics N V Stock (PRQR) Financials Data
Revenue
Net Income
Cash Flow
EPS
Proqr Therapeutics N V Stock (PRQR) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Filius Bart | Director |
Jul 17 '26 |
Buy |
1.72 |
150,000 |
257,925 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 09 '26 |
Buy |
1.74 |
150,000 |
261,000 |
300,000 |
| de Boer Daniel Anton | Chief Executive Officer |
Jul 07 '26 |
Buy |
1.59 |
150,000 |
238,500 |
150,000 |
| Filius Bart | Director |
Jun 26 '26 |
Buy |
1.54 |
150,000 |
231,000 |
150,000 |
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):